PS is a slow-onset, low-ceiling supplement — most users feel "nothing acute" on first dose. Effects emerge over 7-14 days as the HPA-blunting integrates into daily cortisol curves. Don't expect a phenibut-style "felt change."

Onset: Detectable in plasma within 30 min, brain within ~3 h (Toffano 1976 radio-labeled PK). Acute subjective change minimal at any single dose.

Plateau (post-loading, 7-14 days):

• Reduced "stressed-but-wired" feel at end of long training/work days — the classic morning-cortisol-spike + 11 PM-second-wind pattern flattens
• Slightly easier sleep onset on heavy-training days (likely cortisol-blunting downstream)
• Marginal improvement in mental clarity / verbal recall — usually under-noticed
• Reduced perceived soreness 24-48 h post-hard-training (Fahey 1998 replication of subjective signal)
• Most users describe it as "lower-floor" rather than "higher-ceiling" — the day's worst stress moments are less spike-y

For Dylan-profile (high training + business stress + late chronotype):

• The day's cortisol curve flattens — the 8 AM cortisol awakening response is preserved (you still wake up alert), but the post-training mid-morning spike and the late-evening rebound flatten by week 2-3.
• The HPA-axis-driven "still wired at 2 AM" pattern (common in night-owls with overtraining) tends to soften — easier to wind down at midnight.
• Mood baseline trends slightly upward if HPA was dysregulated pre-supplement. If HPA was healthy, no detectable mood change.

Characteristic effects:

• No euphoria, no acute focus boost, no stimulation
• No taper / no rebound on stopping
• Some users report a paradoxical mild stimulation at higher doses (>600 mg) — if PS clears morning cortisol too aggressively without sufficient downstream adrenergic compensation. Usually resolves with split-dosing.

Honest variability: ~30% of healthy non-stressed users feel nothing measurable. ~50% feel the HPA-flattening signal within 2 weeks. ~15-20% notice mood/sleep improvement. <5% have GI upset that limits continuation. State-dependence is real — Dylan's high training volume + business stress profile is the responder phenotype.

• Tolerance buildup: None documented. The mechanism is substrate replenishment (PS is itself a structural lipid, not a receptor ligand). HPA-blunting effects in Hellhammer 2014 persisted across the full 42-day study without escalation needed.
• Cycling not required. Daily continuous use indefinitely is reasonable. No receptor downregulation pathway identified.
• Practical cycling rationale (Dylan use): Skip on full rest weeks / deload weeks. When training stimulus drops 50%+ for 5-7 days, dropping PS to 0-300 mg avoids over-flattening cortisol on days when HPA load is already low. Resume full 600 mg/d when training resumes.
• Indefinite use: Safe based on 6-12 month trial data. Long-term (years) data sparse but no harm signals in clinical or community reports.
• Discontinuation: No taper needed. Effect dissipates within 5-10 days as supplemented PS clears the membrane pool. No rebound HPA hyperactivity.

Synergistic with

• Ashwagandha (KSM-66 600 mg, already V4): Best pairing. Different mechanism — ashwagandha modulates peripheral cortisol synthesis (adrenal level) + has mild GABAergic action; PS modulates central CRH/ACTH (hypothalamic-pituitary level). Stack covers both ends of the HPA axis. Stagger: PS morning + pre-training; ashwagandha evening.
• Rhodiola rosea (200-400 mg, already V4): Adaptogen with mixed monoaminergic + HPA effects. Compatible — different mechanism, no redundancy. Stack works for the high-stress athlete profile.
• Magnesium glycinate (300-400 mg, already V4): Neutral co-administration; magnesium supports HPA regulation independently. No interaction.
• Omega-3 EPA/DHA (2-3 g, already V4): Important synergy — DHA co-administration approximates the bovine-PS molecular species (DHA-rich) using a soy-PS base. Some research-grade products (e.g., Lipogen's PS-Omega3) deliver this as a single conjugated molecule, but separately is fine.
• L-theanine (200 mg) and glycine (3 g, already V4): Compatible. Different anxiolytic/HPA mechanisms.
• Alpha-GPC or CDP-choline (already V4): Synergistic on cognitive endpoint — both support cholinergic membranes; PS supports cholinergic-receptor membrane environment.
• Creatine (5 g, already V4): Neutral; potential additive cognitive support but no direct interaction.

Avoid stacking with

• High-dose corticosteroid medication (prednisone, etc.) — theoretical antagonism on HPA-feedback; clinical relevance unstudied. Discuss with prescriber.
• Anti-cortisol pharmaceuticals (metyrapone, mifepristone): redundant + theoretical over-suppression. Not relevant for Dylan archetype.
• Heavy cumulative HPA-flatteners — if a user is already running ashwagandha 600 mg + rhodiola 400 mg + low-intensity training + chronic stress relief practices, adding 600 mg PS can produce flatness/hypocortisolism-feel. Symptom-titrate.

Neutral / safe co-administration

• All standard V4/V5 supplements (NAC, citicoline, modafinil if applicable, vitamin D3/K2, beta-alanine, vitamin C, curcumin) — no interactions.
• Caffeine — neutral; PS doesn't blunt caffeine's adrenergic effect significantly.
• Most peptides Dylan profile is using/planning (Semax, Selank, BPC-157, TB-500) — neutral.

PS has no clinically significant drug-drug interactions documented in 35+ years of clinical use. This is one of the cleaner interaction profiles in the nootropic space.

Theoretical considerations (low clinical relevance):

• Anticoagulants (warfarin, DOACs): Phospholipids can theoretically influence platelet aggregation in vitro, but no clinical bleeding signals documented at PS supplement doses. Monitor INR if combining with warfarin out of caution; no dose adjustment expected.
• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Both PS and AChE inhibitors support cholinergic function; theoretically additive on cognitive endpoints. Not contraindicated. Relevant only in dementia treatment contexts.
• Corticosteroids (prednisone, dexamethasone, hydrocortisone): PS's HPA-blunting effect could theoretically interfere with the body's own corticosteroid response or compound exogenous corticosteroid effects. No documented clinical issue at supplement doses. If a user is on steroid pulse therapy (asthma flare, autoimmune), pause PS during the pulse out of caution.
• NSAIDs (long-term high-dose): Neutral. No interaction.
• SSRIs / SNRIs / TCAs: Neutral. PS doesn't significantly affect serotonin/NE reuptake.
• MAOIs: Neutral. No documented interaction.
• Stimulants (modafinil, methylphenidate, amphetamines): Neutral. Mechanisms don't overlap.

Special populations:

• Pregnancy/lactation: Insufficient data. Avoid as a precaution.
• Hepatic impairment: No known issue; PS is metabolized via lipid pathways, no CYP involvement.
• Renal impairment: No known issue.

No CYP induction or inhibition documented. PS does not affect hormonal contraceptive efficacy. No food-drug interactions beyond the absorption benefit of co-ingested fat.

PS has minimal pharmacogenomic literature specific to it. Unlike modafinil (CYP) or caffeine (CYP1A2), PS is not a CYP substrate or inhibitor. The relevant genetic variation operates upstream on cortisol regulation rather than on PS itself.

Indirect modifiers of PS response:

• NR3C1 (glucocorticoid receptor) polymorphisms — variants like BclI (rs41423247) and N363S affect glucocorticoid receptor sensitivity. Users with hyper-responsive GR variants (e.g., N363S carriers) tend to have more reactive HPA axes and theoretically larger PS-induced blunting. Limited direct PS-PGx data; inferred from HPA-axis biology.
• FKBP5 — variants modulate cortisol-feedback regulation. Some FKBP5 alleles associated with PTSD-like HPA dysregulation; PS effect may be larger in these phenotypes. Speculative.
• COMT Val158Met (rs4680): Met/Met (slow COMT, "worriers") tend to have higher stress-induced cortisol and may respond more visibly to PS. Val/Val (fast COMT, "warriors") less so. Dylan's COMT status will be inferable from 23andMe raw data via Promethease (June 2026 results).
• 5-HTTLPR (SLC6A4) short/long alleles: S/S allele associated with higher HPA reactivity; potentially larger PS response. Speculative.
• CRHR1 (CRH receptor 1) variants: Modulate central HPA reactivity; likely affect PS efficacy. No direct PGx-PS studies as of 2026.

Practical takeaway for Dylan: PS response is more strongly state-dependent (training load, stress level) than genotype-dependent. After 23andMe results land in June 2026, check FKBP5, NR3C1, COMT, and 5-HTTLPR variants — high-HPA-reactivity haplotypes would reinforce PS as a high-leverage pick. None of these are dose-modifying — just response-likelihood-modifying.

Soy-related allergy alleles: If 23andMe or family history flags soy sensitivity, use sunflower-derived PS.

Brand-quality notes:

• Sharp-PS is the standardized soy-lecithin-derived ingredient produced by Enzymotec (now Frutarom/IFF). Found in NOW, Doctor's Best, Jarrow Soy-PS, and most major branded products. Reproducibly characterized 50% PS content from soybean lecithin.
• Sharp-PS Green = sunflower-derived version; allergen-friendly; pricier.
• PS-IQ = competing branded ingredient; comparable quality.
• "Phosphatidyl serine complex" at low %PS content (e.g., 20% PS from lecithin) — sometimes priced cheaply but you need 3× the cap count for the same dose. Check the label.

For Dylan: NOW Foods Phosphatidylserine 100 mg, 120-cap bottle on iHerb (~$17). Take 3 caps (300 mg) at breakfast + 3 caps pre-training on training days; 3 caps at breakfast only on rest days. 120 caps lasts ~20 training days at 600 mg/d, ~40 rest days at 300 mg/d. Realistic monthly burn ~180-200 caps = $25-30/month. Cheaper option: bulk powder if Dylan tolerates taste; saves ~30%.

Payment: Standard card/PayPal; no gray-market sourcing issues.

Shipping: Standard supplement shipping (no restrictions, no customs flags).

Baseline (before starting)

• Morning salivary cortisol (8 AM) and evening (10 PM) — captures diurnal HPA pattern. Optimal pre-supplement baseline. Direct outcome measure.
• AM serum cortisol if blood draw available — Dylan's June 2026 bloodwork panel should include this.
• DHEA-S — counter-regulatory hormone; useful for cortisol:DHEA-S ratio (HPA balance index).
• Testosterone (free + total) — Starks 2008 showed T:C ratio improved 184%; useful endpoint.
• HRV (RMSSD or DFA-α1) — Oura ring or chest strap. Higher HRV = lower sympathetic tone. PS should bias HRV up over weeks.
• PSQI (Pittsburgh Sleep Quality Index) or simple 1-10 sleep quality VAS daily × 7-14 days pre-dose.
• Perceived Stress Scale (PSS-10) baseline.
• Subjective overtraining symptoms if relevant — soreness, motivation, libido, appetite.

During use

• Daily: subjective stress / mood / motivation VAS (1-10). Track for 2-4 weeks to capture loading-onset.
• Weekly: PSQI or sleep VAS.
• Monthly: subjective overtraining symptoms (1-10), training RPE, soreness recovery time.
• 3 months: repeat AM salivary or serum cortisol. Expect ~15-30% reduction if responder.
• 3-6 months: repeat full hormone panel (T, cortisol, DHEA-S, fasting glucose) — confirms HPA improvements.
• HRV trend over the cycle — expect upward drift on training days vs. pre-PS baseline.

Post-cycle (if cycled)

• After 1-2 weeks off, repeat morning cortisol — should remain stable (no rebound HPA hyperactivity expected, but worth confirming).
• Subjective: does stress reactivity creep back? If yes, restart PS.